ArticleBMC cancer2024

Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.

Boyu Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.